These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20956624)

  • 1. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
    Spataro V
    J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 3. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
    Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
    [No Abstract]   [Full Text] [Related]  

  • 5. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 6. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
    Delomas T; Darné C; Besson C
    Leuk Lymphoma; 2012 Feb; 53(2):332-3. PubMed ID: 21823828
    [No Abstract]   [Full Text] [Related]  

  • 8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
    García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
    Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 13. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.
    Perini GF; Santos FP; Funke V; Ruiz J; Neto BH; Hamerschlak N
    Leuk Res; 2009 Dec; 33(12):e234-5. PubMed ID: 19632720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 16. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 18. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe peripheral arterial disease during nilotinib therapy.
    Le Coutre P; Rea D; Abruzzese E; Dombret H; Trawinska MM; Herndlhofer S; Dörken B; Valent P
    J Natl Cancer Inst; 2011 Sep; 103(17):1347-8. PubMed ID: 21813414
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
    Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
    Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.